<VariationArchive RecordType="classified" VariationID="2498328" VariationName="NM_000153.4(GALC):c.1878_1894del (p.Lys627fs)" VariationType="Deletion" Accession="VCV002498328" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-10-15" DateCreated="2023-04-23" MostRecentSubmission="2023-04-23">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2476305" VariationID="2498328">
      <GeneList>
        <Gene Symbol="GALC" FullName="galactosylceramidase" GeneID="2581" HGNC_ID="HGNC:4115" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>14q31.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="14" Accession="NC_000014.9" start="87933014" stop="87993667" display_start="87933014" display_stop="87993667" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="14" Accession="NC_000014.8" start="88399357" stop="88460008" display_start="88399357" display_stop="88460008" Strand="-" />
          </Location>
          <OMIM>606890</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000153.4(GALC):c.1878_1894del (p.Lys627fs)</Name>
      <CanonicalSPDI>NC_000014.9:87939921:GTGTATACCATTTTTTTG:G</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>14q31.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="14" Accession="NC_000014.9" start="87939922" stop="87939938" display_start="87939922" display_stop="87939938" variantLength="17" positionVCF="87939921" referenceAlleleVCF="AGTGTATACCATTTTTTT" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="14" Accession="NC_000014.8" start="88406266" stop="88406282" display_start="88406266" display_stop="88406282" variantLength="17" positionVCF="88406265" referenceAlleleVCF="AGTGTATACCATTTTTTT" alternateAlleleVCF="A" />
      </Location>
      <OtherNameList>
        <Name>p.Lys627HisfsTer5</Name>
      </OtherNameList>
      <ProteinChange>K601fs</ProteinChange>
      <ProteinChange>K604fs</ProteinChange>
      <ProteinChange>K627fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011853.3" sequenceAccession="NG_011853" sequenceVersion="3" change="g.58626_58642del">
            <Expression>NG_011853.3:g.58626_58642del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000153.4" sequenceAccession="NM_000153" sequenceVersion="4" change="c.1878_1894del" MANESelect="true">
            <Expression>NM_000153.4:c.1878_1894del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000144.2" sequenceAccession="NP_000144" sequenceVersion="2" change="p.Lys627fs">
            <Expression>NP_000144.2:p.Lys627fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001201401.2" sequenceAccession="NM_001201401" sequenceVersion="2" change="c.1809_1825del">
            <Expression>NM_001201401.2:c.1809_1825del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001188330.1" sequenceAccession="NP_001188330" sequenceVersion="1" change="p.Lys604fs">
            <Expression>NP_001188330.1:p.Lys604fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001201402.2" sequenceAccession="NM_001201402" sequenceVersion="2" change="c.1800_1816del">
            <Expression>NM_001201402.2:c.1800_1816del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001188331.1" sequenceAccession="NP_001188331" sequenceVersion="1" change="p.Lys601fs">
            <Expression>NP_001188331.1:p.Lys601fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000014.8" sequenceAccession="NC_000014" sequenceVersion="8" change="g.88406267_88406283del" Assembly="GRCh37">
            <Expression>NC_000014.8:g.88406267_88406283del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000014.9" sequenceAccession="NC_000014" sequenceVersion="9" change="g.87939923_87939939del" Assembly="GRCh38">
            <Expression>NC_000014.9:g.87939923_87939939del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000153.4(GALC):c.1878_1894del (p.Lys627fs) AND Galactosylceramide beta-galactosidase deficiency" Accession="RCV003222546" Version="1">
        <ClassifiedConditionList TraitSetID="1051">
          <ClassifiedCondition DB="MedGen" ID="C0023521">Galactosylceramide beta-galactosidase deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-04-13" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-04-13" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-04-23" MostRecentSubmission="2023-04-23">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="1051" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2446" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Krabbe leukodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Globoid cell leukoencephalopathy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Galactosylceramide beta-galactosidase deficiency</ElementValue>
                <XRef ID="Krabbe+leukodystrophy/4044" DB="Genetic Alliance" />
                <XRef ID="192782005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Galactocerebrosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Leukodystrophy, Globoid Cell</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">GCL</ElementValue>
                <XRef Type="MIM" ID="245200" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">GLD</ElementValue>
                <XRef Type="MIM" ID="245200" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6844" />
                <XRef ID="6844" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Krabbe disease comprises a spectrum ranging from infantile-onset disease (i.e., onset of extreme irritability, spasticity, and developmental delay before age 12 months) to later-onset disease (i.e., onset of manifestations after age 12 months and as late as the seventh decade). Although historically 85%-90% of symptomatic individuals with Krabbe disease diagnosed by enzyme activity alone have infantile-onset Krabbe disease and 10%-15% have later-onset Krabbe disease, the experience with newborn screening (NBS) suggests that the proportion of individuals with possible later-onset Krabbe disease is higher than previously thought. Infantile-onset Krabbe disease is characterized by normal development in the first few months followed by rapid severe neurologic deterioration; the average age of death is 24 months (range 8 months to 9 years). Later-onset Krabbe disease is much more variable in its presentation and disease course.</Attribute>
                <XRef ID="NBK1238" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301416</ID>
                <ID Source="BookShelf">NBK1238</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="AAP, 2021">
                <URL>https://publications.aap.org/pediatrics/article/148/3/e2021053126/181065/Leukodystrophies-in-Children-Diagnosis-Care-and</URL>
                <CitationText>Leukodystrophies in Children: Diagnosis, Care, and Treatment, Pediatrics (2021) 148 (3): e2021053126.</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Krabbe-Infantile.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased galactocerebrosidase, elevated psychosine, Krabbe Disease (infantile form), 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Krabbe-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Krabbe disease: galactocerebrosidase deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Krabbe-Later-Onset.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased galactocerebrosidase, mildly elevated psychosine, Krabbe Disease (late-onset form), 2022</CitationText>
              </Citation>
              <XRef ID="487" DB="Orphanet" />
              <XRef ID="C0023521" DB="MedGen" />
              <XRef ID="MONDO:0009499" DB="MONDO" />
              <XRef Type="MIM" ID="245200" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7321486" SubmissionDate="2023-04-17" DateLastUpdated="2023-04-23" DateCreated="2023-04-23">
        <ClinVarSubmissionID localKey="SUB13086513" submittedAssembly="GRCh38" title="SUB13086513" />
        <ClinVarAccession Accession="SCV003915843" DateUpdated="2023-04-23" DateCreated="2023-04-23" Type="SCV" Version="1" SubmitterName="Foundation for Research in Genetics and Endocrinology, FRIGE's Institute of Human Genetics" OrgID="505565" OrganizationCategory="other" OrgAbbreviation="FRIGE - IHG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-04-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>A Homozygous deletion in exon 16 of the GALC gene that results in a frameshift and premature truncation of the protein 5 amino acids downstream to codon 627 was detected. The observed variant c.1878_1894del (p.Lys627HisfsTer5) has not been reported in the 1000 genomes and gnomAD databases. The in silico prediction of the variant is damaging by MutationTaster2. The reference codon is conserved across species. In summary, the variant meets our criteria to be classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">0</Age>
              <Age Type="maximum" age_unit="years">9</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <NamePlatform>Illumina sequencing platform</NamePlatform>
              <TypePlatform>Next-generation sequencing</TypePlatform>
              <Description>DNA was used to perform targeted gene capture using a custom capture kit. Libraries were sequenced to mean &gt;80-100X coverage on Illumina sequencing platform. Sequence obtained were aligned to human references genome using BWA program and analyzed using Picard and GATK-Lite toolkit to identify variants in the targeted genes relevant to clinical indication.</Description>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Homozygote" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GALC">
              <Name>galactosylceramidase</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000153.4:exon 16</GeneLocation>
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">B-9902</Name>
            <Name>p.Lys627HisfsTer5</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000153.4:c.1878_1894del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="245200" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13086513</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7321486" TraitType="Disease" MappingType="XRef" MappingValue="245200" MappingRef="OMIM">
        <MedGen CUI="C0023521" Name="Galactosylceramide beta-galactosidase deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

